How Epoxy-Oxylipins Guide Monocytes During Inflammatory Resolution
January 21, 2026
Brand Name :
TicoVac
Synonyms :
tick-borne encephalitis vaccine
Class :
Vaccines, Inactivated, Viral
Dosage Forms & Strengths
Suspension
0.25ml prefilled syringe
0.5ml prefilled syringe
Administer dose of 0.5 ml intramuscularly, then repeat again for 2 weeks to 3 months after first dose and then for 5 to 12 months after second dose
Dosage Forms & Strengths
Suspension
0.25ml prefilled syringe
0.5ml prefilled syringe
For <1 year old: Safety and efficacy not determined
For 1 to 15 years old:
Administer dose of 0.25 ml via intramuscularly then repeat for 1 to 3 months after first dose and for 5 to 12 months after second dose
For ≥16 years old:
Administer dose of 0.5 ml intramuscularly, then repeat again for 2 weeks to 3 months after first dose and then for 5 to 12 months after second dose
Refer to adult dosing
the therapeutic activity of the tick-borne encephalitis vaccine (whole virus, inactivated) may be reduced
Actions and Spectrum
Inactivated vaccines contain killed virus particles and viral proteins. When the vaccine is administered, it stimulates the immune system to recognize these viral components as foreign and mount an immune response.
Frequency defined
>10%
Injection site tenderness
Local pain
Headache
Local pain
Injection site tenderness
1-10%
Muscle pain
Fatigue
Headache
Fever
Restlessness
Post marketing Reports
Hypersensitivity
Visual impairment
Herpes zoster
Anaphylactic reaction
Photophobia
Tachycardia
Eye pain
Tinnitus
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
When the inactivated vaccine is administered, it triggers the immune system to recognize the viral components as foreign. This recognition leads to the production of antibodies specific to the tick-borne encephalitis virus.
Pharmacodynamics
Tick-borne encephalitis vaccination is the production of antibodies, which are proteins that can specifically recognize and neutralize the tick-borne encephalitis virus.
Pharmacokinetics
Limited information available on ADME.
Administration
Tick-borne encephalitis vaccine is administered via intramuscularly in suspension form.
Patient information leaflet
Generic Name: tick-borne encephalitis vaccine
Why do we use tick-borne encephalitis vaccine?
The tick-borne encephalitis vaccine indicated in the prevention of tick-borne encephalitis.
The vaccine helps reduce the risk of contracting the virus and developing the associated neurological complications.